COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,234 Articles (22,733 medRxiv, 8,501 bioRxiv)

Most recent first Previous |  Page 1924: Articles 19231-19240  | Next

Implementing Building-Level SARS-CoV-2 Wastewater Surveillance on a University Campus
Gibas, C. J., Lambirth, K., Mittal, N., Juel, M. A. I., Bharati Barua, V., Roppolo Brazell, L., Hinton, K., Lontai, J., Stark, N., Young, I., Quach, C., Russ, M., Kauer, J., Nicolosi, B., Akella, S., Tang, W., Chen, D., Schlueter, J., Munir, M.
10.1101/2020.12.31.20248843 — Posted: 2021-01-04
Survival analysis of all critically ill patients with COVID-19 admitted to the main hospital in Mogadishu, Somalia, 30 March to 12 June 2020: what interventions are proving effective?
Ali, M. M., Rahman Malik, M., Ahmed, A. Y., Bashir, A. M., Mohamed, A., Abdi, A., Obtel, M.
10.1101/2021.01.01.20248966 — Posted: 2021-01-04
Can Catastrophe Theory explain expansion and contagious of Covid-19?
Caetano, M. A. L.
10.1101/2021.01.02.21249133 — Posted: 2021-01-04
Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data
Bello-Chavolla, O. Y., Antonio-Villa, N. E., Fernandez-Chirino, L., C. Guerra, E., Fermin-Martinez, C. A., Marquez-Salinas, A., Vargas-Vazquez, A., Bahena-Lopez, J. P.
10.1101/2021.01.02.21249141 — Posted: 2021-01-04
Changes in COVID-19-related outcomes and the impacts of the potential risk factors over time: a follow-up analysis
Yu, Y., Gu, T., Valley, T. S., Fritsche, L. G., Mukherjee, B.
10.1101/2021.01.02.21249140 — Posted: 2021-01-04
Analysis of the intensity of the COVID-19 epidemic in Berlin towards an universal prognostic relationship
Below, D., Mairanowski, J., Mairanowski, F.
10.1101/2021.01.03.21249117 — Posted: 2021-01-04
THE INFLUENCE OF HLA GENOTYPE ON SUSCEPTIBILITY TO, AND SEVERITY OF, COVID-19 INFECTION
Langton, D. J., Bourke, S. C., Lie, B. A., Reiff, G., Natu, S., Darlay, R., Burn, J., Echevarria, C.
10.1101/2020.12.31.20249081 — Posted: 2021-01-04
The Joint Impact of COVID-19 Vaccination and Non-Pharmaceutical Interventions on Infections, Hospitalizations, and Mortality: An Agent-Based Simulation
Patel, M. D., Rosenstrom, E., Ivy, J. S., Mayorga, M. E., Keskinocak, P., Boyce, R. M., Hassmiller Lich, K., Smith, R. L., Johnson, K. T., Swann, J. L.
10.1101/2020.12.30.20248888 — Posted: 2021-01-04 Discussion: Onsite
Sub-5-minute Detection of SARS-CoV-2 RNA using a Reverse Transcriptase-Free Exponential Amplification Reaction, RTF-EXPAR
Carter, J. G., Orueta Iturbe, L., Duprey, J.-L. H. A., Carter, I. R., Southern, C. D., Rana, M., Bosworth, A., Beggs, A. D., Hicks, M. R., Tucker, J. H. R., Dafforn, T. R.
10.1101/2020.12.31.20248236 — Posted: 2021-01-04
Implications in the quantitation of SARS-CoV2 copies in concurrent nasopharyngeal swabs, whole mouth fluid and respiratory droplets
Kannian, P., Jayaraman, B. G., Alamelu, S., Lavanya, C., Kumarasamy, N., Rajan, G., Ranganathan, K., Mahanathi, P., Ashwini, V., Challacombe, S. J., Webster-Cyriaque, J., Johnson, N. W.
10.1101/2021.01.03.21249157 — Posted: 2021-01-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).